Search

Displaying results 2251 - 2260 of 7058 in total
  1. Drug

    Evategrel

    go.drugbank.com/drugs/DB21691
    Experimental

    Evategrel is a small molecule drug. Evategrel has a monoisotopic molecular weight of 471.11 Da.

  2. Drug

    Lecufexor

    go.drugbank.com/drugs/DB21714
    Experimental

    Lecufexor is a small molecule drug. Lecufexor has a monoisotopic molecular weight of 618.05 Da.

  3. Drug

    Matsupexole

    go.drugbank.com/drugs/DB21715
    Experimental

    Matsupexole is a small molecule drug. Matsupexole has a monoisotopic molecular weight of 446.25 Da.

  4. Drug

    Balinatunfib

    go.drugbank.com/drugs/DB21728
    Investigational

    Balinatunfib is a small molecule drug. Balinatunfib has a monoisotopic molecular weight of 502.19 Da.

  5. Drug

    Rogocekib

    go.drugbank.com/drugs/DB21739
    Investigational

    Rogocekib is a small molecule drug. Rogocekib has a monoisotopic molecular weight of 408.15 Da.

  6. Drug

    Sotorasib

    go.drugbank.com/drugs/DB15569
    ApprovedInvestigational

    [A187547] Sotorasib was granted FDA approval on May 28, 2021,[L34288] followed by the European Commission's approval on January 6, 2022.[L56070] … [A187550] Mutant KRAS discovered in 1982 but was not considered a druggable target until the mid-2010s.[A235168] It is the first experimental KRAS inhibitor.

    Synonyms: 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-(1M)-1-[4-methyl-2-(propan-2-yl)pyridin-3-yl]-4-[(2S)-2- methyl-4-(prop-2-enoyl)piperazin-1-yl]pyrido[2,3-d]pyrimidin-2(1H)-one
  7. Drug

    1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol))

    go.drugbank.com/drugs/DB11331
    ApprovedWithdrawn

    Palmitoyloleoyl-phosphatidylglycerol was a component of Surfaxin, discontinued in 2017, which acted as a surfactant [FDA Label].

  8. Drug

    Delafloxacin

    go.drugbank.com/drugs/DB11943
    ApprovedInvestigational

    Delafloxacin is a fluoroquinolone antibiotic which has been used in trials studying the treatment and basic science of Gonorrhea, Hepatic Impairment, Bacterial Skin Diseases, Skin Structure Infections,

  9. Drug

    Osimertinib

    go.drugbank.com/drugs/DB09330
    ApprovedInvestigational

    testing and which has progressed following therapy with a first-generation EGFR tyrosine kinase inhibitor. … Approximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs due to the presence of specific activating EGFR mutations within the tumour cells.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  10. Drug

    Rezivertinib

    go.drugbank.com/drugs/DB21471
    Investigational

    Rezivertinib has a monoisotopic molecular weight of 486.24 Da. … Rezivertinib is a small molecule drug. The usage of the INN stem '-ertinib' in the name indicates that Rezivertinib is a epidermal growth factor receptor (EGFR) inhibitor.